Search company, investor...

Phytomedics

phytomedics.com

Founded Year

1996

Stage

Series B | Alive

Total Raised

$16.5M

Last Raised

$9M | 15 yrs ago

About Phytomedics

Phytomedics is a biopharmaceutical company based in New Jersey with a broad portfolio of novel compounds for chronic diseases. The lead compound is in clinical development and has shown extraordinary results in clinical trials for the treatment of auto immune disorders like rheumatoid arthritis. The company's platform technology is the basis of their large portfolio of novel therapeutic compounds.

Headquarters Location

1085 Cranbury South River Road Suite 8

Jamesburg, New Jersey, 08831,

United States

609-655-0715

Missing: Phytomedics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Phytomedics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Phytomedics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Phytomedics is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Latest Phytomedics News

Photosynthetic Harvest Milks Green Plants for Human, Microbial Proteins

Nov 12, 2018

They don't call them pharmaceutical plants for nothing. Plants—the green kind—were once the starting points for about 80% of all pharmaceuticals. During the 19 th century, leaves, bark, stems, and roots were routinely harvested and processed, in brick-and-mortar plants, to produce lotions, powders, tablets, and elixirs that lined the shelves of apothecaries. Even today such highly processed products as codeine begin their existence in poppy fields. With the advent of genetic engineering it's now possible to coax plants into producing pharmaceutical-grade products that nature never intended them to make. Which is why Phytomedics Inc. (Willingboro, NJ) believes there may be a pharmaceutical "plant" in your future. Phytomedics uses its proprietary Rhizosecretion technology to "milk" green plants for a variety of human and microbial proteins. Rhizosecretion, developed by Ilya Raskin at Rutgers University (New Brunswick, NJ) and exclusively licensed to Phytomedics, takes advantage of the ability of green plants grown in water (hydroponically), to synthesize and secrete large quantities of bioactive compounds from their roots. Using genetic material from humans, jellyfish, and microbes, Phytomedics scientists have engineered the roots of plants to produce and exude large quantities of recombinant proteins, continuously, into a hydroponic medium. Recombinant proteins are widely used as pharmaceuticals and as industrial and food processing enzymes. While the need for recombinant proteins is increasing each year, the growth of the market is limited, due to the relatively high costs of protein manufacture using conventional microbial and animal cell culture systems. Protein manufacture using Rhizosecretion offers a low cost, large-scale recombinant protein production system with simplified downstream processing. According to Ira Pastor, director of business development for Phytomedics, his company is now optimizing a molecular farming system capable of continuously secreting recombinant proteins without the need to destroy the actual plant material, as is the case with other transgenic plant protein production systems. "We are also developing methods for increasing protein yield during the scale-up production process, such that the protein secreting plants can be indefinitely propagated from seeds or cuttings at a very low cost," Pastor said. "We are now initiating collaborations with industrial partners to jointly proceed with further development of the technology for a wide range of commercial applications." Harvesting, Discovery Technology Phytomedics has two harvesting techniques under development, both falling into a general category known as "phytosecretion." Rhizosecretion, described above, exploits a green plant's ability to exude large quantities of organic compounds and proteins from its roots into a simple aqueous medium. Rhizosecretion is currently used to manufacture bioactive compounds identified in the RhizEx libraries and to produce recombinant proteins from tobacco and tomato. Phyllosecretion exploits leaf guttation as a medium to continuously wash recombinant proteins away from a living plant. Guttation fluid, commonly known as "dew," is exuded by a plant every morning and can be transformed into a concentrated solution of recombinant proteins. In addition to research into recombinant protein biomanufacturing, PHI has developed a broad range of integrated life science biotechnologies for applications such as pharmaceutical and agrichemical discovery, gene amplification for crop engineering, bioactive peptide development, and production of scientifically optimized nutraceuticals. One such technology are RhizEx libraries—proprietary mixtures of structurally novel natural products produced and/or secreted by hydroponically cultivated plant roots exposed to various stresses (elicitors). Currently, the libraries include elicited and non-elicited root extracts (elicidates) and exudates of 600 plant species belonging to at least 150 families (approx. 3400 samples). RhizEx samples scored a remarkable 20% hit rates in several internal anti-microbial and crop protection assays. Hit rates for conventional plant extracts usually do not exceed 1–2%, and are mainly produced by well known compounds with no commercial potential. Phytomedics' proprietary elicitation process is the key to novelty, diversity, and bio-activity of RhizEx libraries. By mimicking various biological and environmental stresses, elicitation triggers the production of bio-active natural products absent under normal conditions. PMI has demonstrated that elicitation adds another dimension to the chemodiversity of plant natural products, greatly increasing the chances of finding novel lead compounds. A major advantage of RhizEx libraries is that any lead compound contained in the libraries can be efficiently manufactured on a small or large-scale using rhizosecretion or phyllosecretion, thus guaranteeing re-supply of an active ingredient in large quantities. For more information: Ira Pastor, Director for Business Development, Phytomedics Inc., Hill International Building, Suite 3, One Levitt Parkway, Willingboro, NJ 08046. Tel: 609-835-1600, ext. 1. Email: ipastor@phiroots.com. To learn about Rhizosecretion: Ilya Raskin, Professor, Rutgers University Biotechnology Center, Foran Hall, Cook College, 59 Dudley Rd., New Brunswick, NJ 08901-8520. Tel. : 732-932-8734, ext. 227. Email: raskin@aesop.rutgers.edu. By Angelo DePalma

Phytomedics Frequently Asked Questions (FAQ)

  • When was Phytomedics founded?

    Phytomedics was founded in 1996.

  • Where is Phytomedics's headquarters?

    Phytomedics's headquarters is located at 1085 Cranbury South River Road, Jamesburg.

  • What is Phytomedics's latest funding round?

    Phytomedics's latest funding round is Series B.

  • How much did Phytomedics raise?

    Phytomedics raised a total of $16.5M.

  • Who are the investors of Phytomedics?

    Investors of Phytomedics include Inventages Venture Capital, Burrill & Company, Poalim Equity and Koonras Technologies.

  • Who are Phytomedics's competitors?

    Competitors of Phytomedics include Humanetics, Bellicum Pharmaceuticals, Clovis Oncology, Intarcia Therapeutics, Protagonist Therapeutics, Intercept Pharmaceuticals, Neuraltus Pharmaceuticals, Fibrotech Therapeutics, Galleon Pharmaceuticals, Cytochroma and 16 more.

Compare Phytomedics to Competitors

I
Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

H
Humanetics

Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a highly selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.

Q
QuatRx Pharmaceuticals

QuatRx Pharmaceuticals Company is focused on discovering, licensing, developing and commercializing compounds in the endocrine, metabolic and cardiovascular therapeutic areas. In addition to QRX-431, QuatRx currently has three product candidates in clinical development. QuatRx

C
Cryptopharma

Cryptopharma is a Company focused on the discovery and development of anti-inflammatory therapeutic agents for treatment of pulmonary diseases. The company's initial focus is on the development of CP92, a treatment of Cystic Fibrosis. Second generation compounds are in development with the potential to treat other inflammatory conditions including asthma and chronic obstructive pulmonary disease (COPD). See www.cryptopharma.com

N
Neuraltus Pharmaceuticals

Neuraltus Pharmaceuticals is a privately-held biopharmaceutical company dedicated to developing and commercializing innovative therapeutics that address critical unmet needs for patients and physicians in the treatment of neurodegenerative diseases. The Company is collaborating with global ALS specialists and seeking input from patient advocacy organizations to help inform the clinical development path and better understand the needs of people affected by the disease.

A
Asterion

Asterion is a manufacturer of analog semiconductors.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.